NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer

NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Phase II Study of NBTXR3 Activated by Radiation and Combined With Pembrolizumab for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma With Limited PD-L1 Expression or Refractory to PD-1 Blockade

This phase II trial investigates the effect of NBTXR3, radiation therapy, and pembrolizumab in treating patients with head and neck squamous cancer that has come back (recurrent) or has spread to other places in the body (metastatic). NBTXR3 may help make tumor cells more sensitive to the radiation therapy. Radiation therapy, such as stereotactic body radiation therapy, uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. And hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving NBTXR3, radiation therapy, and pembrolizumab may kill more tumor cells.

PRIMARY OBJECTIVE: I. To evaluate tumor response of hafnium oxide-containing nanoparticles NBTXR3 (NBTXR3) activated by radiation therapy (RT) in combination with pembrolizumab in patients with recurrent/metastatic (R/M) head and neck squamous cell cancer (HNSCC). SECONDARY OBJECTIVES: I. To assess unacceptable treatment-related toxicity of NBTXR3 activated by RT in combination with pembrolizumab in patients with R/M HNSCC. II. To assess the safety profile of NBTXR3 activated RT in combination with pembrolizumab in patients with R/M HNSCC. III. To evaluate time-to-event outcomes of NBTXR3 activated by RT in combination with pembrolizumab in patients with R/M HNSCC. EXPLORATORY OBJECTIVES: I. To associate radiomic measurements with outcomes of treatment with NBTXR3 activated by RT in combination with pembrolizumab. II. To evaluate biomarkers of response in subjects treated with NBTXR3 activated by RT in combination with pembrolizumab. OUTLINE: Patients receive hafnium oxide-containing nanoparticles NBTXR3 via injection intratumorally or intranodally on day 1. Beginning as early as day 3 and within 8 days of NBTXR3 injection, patients undergo stereotactic body radiation therapy (SBRT) every other day (QOD) or hypofractionated RT once daily (QD) over 1-2 weeks at the discretion of the treating radiation oncologist. Starting on the same day as radiation therapy, patients also receive pembrolizumab intravenously (IV) over 30 minutes every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 6 weeks for 2 years.

Patients receive hafnium oxide-containing nanoparticles NBTXR3 via injection intratumorally or intranodally on day 1. Beginning as early as day 3 and within 8 days of NBTXR3 injection, patients undergo SBRT QOD or hypofractionated RT QD over 1-2 weeks at the discretion of the treating radiation oncologist. Starting on the same day as radiation therapy, patients also receive pembrolizumab IV over 30 minutes every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.

Will be estimated using the method of Kaplan-Meier. Median times and 95% the determination of best objective response.

Time from NBTXR3 injection to local, regional or distant failure or death from any cause, whichever occurs first, assessed up to 2 years

Will be defined as evidence of disease recurrence or progression by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and/or histologically confirmed within 2 cm of the radiation planning target volume (PTV).

Will be defined as evidence of disease recurrence or progression by RECIST version 1.1 and/or histologically confirmed that is 2 cm or more outside the PTV and within the organ that received stereotactic body radiation therapy (SBRT).

Will be defined as occurrence of new metastatic lesion(s) that were not identified at baseline (prior to NBTXR3 injection) or evidence of disease progression in metastatic sites identified at baseline that are outside of the organ receiving SBRT. Evidence of disease should be confirmed by RECIST version 1.1 and/or histologically.

Will be assessed per RECIST version 1.1, for the target and non-target lesion(s). Best response will be assessed as well.

Time from first documented complete or partial response to radiographically confirmed disease progression or death from any cause, whichever occurs first.

Will be defined as any grade >= 3 adverse event, excluding dermatitis and mucositis as per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.

Inclusion Criteria: Patients with biopsy proven R/M HNSCC that is considered incurable by local therapies. Participant must have at least 2 lesions At least one lesion will be the target lesion, which will be injected with NBTXR3 and radiated and must be in either the head and neck (HN) or lung or liver. The other lesion will be a non-target lesion, which will not be treated with NBTXR3 or RT, but will be followed for response. Prior systemic therapy (i.e., chemotherapy or targeted therapy) given as part of multimodal treatment for locally advanced disease is allowed. Prior anti-PD-1/L1 therapy allowed in the PD-1 refractory cohort (cohort 2) Have results from testing of human papillomavirus (HPV) status for oropharyngeal cancer defined as p16 immunohistochemistry (IHC) testing using CINtec p16 Histology assay, or equivalent, and a 70% cutoff point. If HPV status previously tested using aforementioned method or an equivalent, no additional testing needed. Oral cavity, hypopharynx, and larynx cancer are not required to undergo HPV testing by p16 IHC as by convention these tumor locations are assumed to be HPV negative Have provided tissue for PD-L1 biomarker analysis from a core or excisional biopsy, fine needle aspirate (FNA) not adequate. A newly obtained biopsy (within 90 days prior to NBTXR3 injection is preferred), but an archival sample is acceptable. PD-1/L1 naive patients with 1% =< combined positive score (CPS) < 20 based on IHC testing. PD-1/L1 refractory patients all CPS levels allowed Amenable to undergo the image guided intratumoral/intranodal injection of NBTXR3 in up to 3 target lesions, as per investigator or treating physician discretion. For the HN target lesions (< 60 cm^3 per site, total volume < 120 cm^3) may be injected and irradiated, including the primary tumor and involved lymph node(s). For the lung or liver target lesion no maximum volume threshold has been defined. However, target lesions must be amenable to receive NBTXR3 injection and RT (50 Gy in 4 fx or 60 Gy in 10 fx) The selected target lesion and non-target lesion should be measurable as per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 on cross sectional imaging and repeated measurements at the same anatomical location should be achievable Target lesion(s) must be located in the HN or lung or liver Target lesion must be amenable to receive RT regimens specified in this protocol at the discretion of the investigator or treating radiation oncologist. Nodal target lesions must be ≥15mm (short axis) based on CT (slice thickness of 5 mm or less) or MRI Age >= 18 years Eastern Cooperative Oncology Group (ECOG) performance status 0-2 Hemoglobin >= 9.0 g/dL Absolute neutrophil count (ANC) >= 1,000/mm^3 Platelet count >= 100,000/mm^3 Leukocytes >= 1500/mm^3 Calculated (Calc.) creatinine clearance > 40 mL/min Total bilirubin =< 2.0 mg/dL Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) or =< 5 x ULN for patients with liver metastasis For patients with lung metastases, adequate lung function with expiratory volume in 1 second (FEV1) >= 0.8 L or >= 35% predicted and carbon monoxide diffusing capability (DLCO) >= 40% with or without bronchodilator within 28 days prior to NBTXR3 injection Patients who meet the criterion above without oxygen (O2), but need acute (started within 7 +/- 3 days) supplemental oxygen due to tumor-caused obstruction/hypoxia are eligible, provided the amount of the O2 needed has been stable Negative urine or serum pregnancy test =< 7 days prior to NBTXR3 injection in all women of child-bearing potential (WOCBP). WOCBP must agree to follow instructions for method(s) of contraception for the duration the entire study period and 6 months after the last dose of anti-PD-1 treatment. Local laws and regulations may require use of alternative and/or additional contraception methods. WOCBP who are continuously not heterosexually active are exempt from contraceptive requirements but should still undergo pregnancy testing Signed informed consent form (ICF) indicating that participant understands the purpose of, and procedures required for, the study and is willing to participate in the study Exclusion Criteria: Diagnosis other than HNSCC R/M with disease that is suitable for local therapy administered with curative intent Less than 6-month time interval from prior radiation to the HN given as part of multimodal treatment for locally advanced disease Prior radiation to the lung or liver target lesions History of severe immune-related adverse events observed with previous immunotherapy (anti-PD-1/L1) or known sensitivity (grade >= 3) to any excipients Has received any approved or investigational anti-neoplastic agent or immunotherapy within 4 weeks prior to NBTXR3 injection. Except anti-PD-1 therapy for patients assigned to cohort 2 (PD-1/L1 refractory), which will not require a washout window. A reduced washout window may be considered for therapies with short half-lives (i.e., kinase inhibitors) after discussion with Nanobiotix and investigator Has not recovered from adverse events (AEs) due to previous anti-neoplastic or immune-oncology therapy and/or interventions (including radiation) to =< grade 1. Participants with alopecia and =< grade 2 neuropathy may be eligible Symptomatic central nervous system metastases and/or carcinomatous meningitis Participants with previously treated brain metastases may participate provided that those lesions are radiologically stable (i.e., without evidence of progression for at least 4 weeks by repeat imaging at screening), clinically stable, and without requirement of steroid treatment for at least 14 days prior to NBTXR3 injection Active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (i.e., thyroxine, insulin, or physiologic corticosteroid replacement [=< 10 mg prednisone] therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment At screening, past medical history of: Drug related pneumonitis Idiopathic pulmonary fibrosis (IPF) Unresolved organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia) Unresolved radiation related Pneumonitis Bronchopulmonary hemorrhage Abdominal hemorrhage Any grade 4 radiation related toxicity Unresolved gastrointestinal (GI) related events Diverticulitis Intra-abdominal abscess GI obstructions Abdominal carcinomatosis Any known risk factor for bowel perforation Any live-virus vaccine therapy used for prevention of infectious diseases administered within 4 weeks prior to NBTXR3 injection Exception of other vaccines (e.g. pneumonia) is at the discretion of the treating physician after conducting a personalized risk assessment on a case by case basis Prior allogenic stem cell transplantation or organ allograft Known contraindication to iodine-based or gadolinium-based IV contrast A history of prior malignancy other than the HNSCC. Subjects with a history of basal or squamous cell carcinoma of the skin, superficial bladder cancer, in situ cervical or breast cancer, prostate cancer in watchful wait, or those that have received curative therapy with no disease recurrence for >= 2 years may be enrolled Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, renal failure, cardiac arrhythmia, or psychiatric illness that would limit compliance with treatment Known active, uncontrolled (high viral load) human immunodeficiency virus (HIV) or hepatitis B or hepatitis C infection Female patients who are pregnant or breastfeeding Women of child-bearing potential and their male partners who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period and up to 6 months, for females, and 220 days for males after the last dose of anti-PD-1. Acceptable methods of contraception are those that, alone or in combination, result in a failure rate of < 1% per year when used consistently and correctly Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments